You may also notice itching, irritation, or redness at the injection site
Set an alarm on your phone so you're sure not to miss your injection date
Nevertheless, the team did emphasize that the short follow-up period in their study may be insufficient to fully capture the chronic trajectory of glaucoma development, particularly given the recent FDA approval of tirzepatide
The two effects partially cancel out, and many patients report less prednisone-related weight gain when they're already on Zepbound
In this article, Alessandra (Ale) Vignola, President of Cardiovascular & Metabolic, explores the need for sustainable, patient-first solutions in GLP-1 clinical trials from personalized approaches to behavioral and social support
Metropolis Healthcare is the most explicit about it: On the GLP-1 front, the receptor agonist market in India is currently valued at USD 110 million in 2024 and is projected to grow to USD 500 million by 2030